Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 7/20 | 0.43 |
| ▸ | ECE1 | P42892 | 7/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633563 | 1.00 | MME (0.43) | MMEECE1HCAR2GRM5ALDH1A1 | |
| SCHEMBL10694244 | 0.84 | ALDH1A1 (0.37) | MMEECE1HCAR2ALDH1A1KDM4E | |
| SCHEMBL6449051 | 0.84 | CYP1A2 (0.44) | ALDH1A1KDM4ECYP1A2CYP3A4MAPT | |
| SCHEMBL30515632 | 0.84 | CYP1A2 (0.44) | ALDH1A1KDM4ECYP1A2CYP3A4MAPT | |
| SCHEMBL2953233 | 0.83 | KDM4E (0.47) | MMEECE1HCAR2GRM5ALDH1A1 | |
| SCHEMBL15022608 | 0.80 | KDM4E (0.57) | MMEECE1HCAR2GRM5ALDH1A1 | |
| SCHEMBL23122854 | 0.78 | CYP2C19 (0.50) | MMEECE1HCAR2GRM5CYP1A2 | |
| SCHEMBL17771436 | 0.78 | GRM5 (0.42) | MMEECE1HCAR2GRM5PTGDR2 | |
| SCHEMBL436732 | 0.78 | MME (0.40) | MMEECE1HCAR2GRM5PTGDR2 | |
| SCHEMBL5392887 | 0.78 | MME (0.40) | MMEECE1HCAR2GRM5PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466790-B | Preparation method of alpha-sulfinylated carbonyl compound | 西北师范大学 | 2024-05-28 | — | — | CN | claimed |
| CN-117466790-A | Preparation method of alpha-sulfinylated carbonyl compound | 西北师范大学 | 2024-01-30 | — | — | CN | claimed |
| US-12338203-B2 | Urea compound for antagonizing LPA1 receptor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-24 | — | — | US | disclosed |
| US-12312348-B2 | RET inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2025-05-27 | — | — | US | disclosed |
| CN-117466790-B | Preparation method of alpha-sulfinylated carbonyl compound | 西北师范大学 | 2024-05-28 | — | — | CN | disclosed |
| CN-117466790-A | Preparation method of alpha-sulfinylated carbonyl compound | 西北师范大学 | 2024-01-30 | — | — | CN | disclosed |
| US-20230097871-A1 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2023-03-30 | — | — | US | disclosed |
| EP-4008405-A1 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | Taisho Pharmaceutical Co., Ltd. (JP) | 2022-06-08 | — | — | EP | disclosed |
| US-20220119382-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| CN-114206832-A | Urea compounds antagonizing LPA1 receptor | 大正制药株式会社 | 2022-03-18 | — | — | CN | disclosed |
| EP-3891148-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2008-08-14 | — | — | US | disclosed |
| CN-101124213-A | Sulfonylamino cyclic derivatives and uses thereof | SERONO LAB (CH) | 2008-02-13 | — | — | CN | disclosed |
| EP-1828160-A1 | SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006067114-A1 | SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2006-06-29 | — | — | WO | disclosed |
| US-6784167-B2 | TREATING OSTEOPOROSIS, OSTEOPENIA, OVARIAN CANCER, BREAST CANCER, ENDOMETRIAL CANCER, ENDOMETRIOSIS, PROSTATE CANCER, ACNE, ANDROGEN-DEPENDENT HAIR LOSS, NON-INSULIN-DEPENDENT DIABETES MELLITUS, OR HYPERCHOLESTEROLEMIA. | BAYER PHARMACEUTICALS CORPORATION | 2004-08-31 | — | — | US | disclosed |
| EP-1326829-A2 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE-II INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20030087952-A1 | 17-Beta-hydroxysteroid dehydrogenase-II inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2003-05-08 | — | — | US | disclosed |
| WO-2002026706-A2 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE-II INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2002-04-04 | — | — | WO | disclosed |
| US-6103743-A | Unsaturated amino acid derivatives | ALLELIX NEUROSCIENCE, INC. (US) | 2000-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338203-B2 | Urea compound for antagonizing LPA1 receptor | LPAR1, LPAR2, LPAR3 | MME 2554/4885ECE1 953/4885HCAR2 177/4885 |
| US-20220119382-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | RET, SLC10A2, REL | MME 1226/4885ECE1 1890/4885HCAR2 397/4885 |
| US-20230097871-A1 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | LPAR1, LPAR2, LPAR3 | MME 2554/4885ECE1 953/4885HCAR2 177/4885 |
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | GLS2, SRM, GLS | MME 1335/4885ECE1 193/4885HCAR2 1856/4885 |
| US-12312348-B2 | RET inhibitors, pharmaceutical compositions and uses thereof | RET, SLC10A2, REL | MME 1226/4885ECE1 1890/4885HCAR2 397/4885 |
| US-20030087952-A1 | 17-Beta-hydroxysteroid dehydrogenase-II inhibitors | HSD3B1, HSD3B2, HSD17B1 | MME 4004/4885ECE1 2135/4885HCAR2 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.